Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00000646

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

1993-03-31

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Pentoxifylline, Virus Replication, Tumor Necrosis Factor, Drug Evaluation, Acquired Immunodeficiency Syndrome, Cachexia, Drug Synergism

Brief summary

To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.

Detailed description

Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity. Twenty-seven AIDS patients with elevated TNF and less than 300 CD4 cells are given pentoxifylline 3 times a day for 8 weeks. If no significant changes are seen in virologic, immunologic, or related measures, 27 additional patients are given a higher dose of pentoxifylline 3 times a day for eight weeks.

Interventions

DRUGPentoxifylline

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Concurrent Medication: Required: * Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), or a combination thereof, at current dosage for the 8 weeks of study treatment. * Prophylaxis (e.g., aerosolized pentamidine, trimethoprim / sulfamethoxazole (TMP / SMX), dapsone for Pneumocystis carinii pneumonia (PCP) if CD4 cell count is \< 200 cells/mm3 Allowed: * Concurrent maintenance therapy for opportunistic infections. Prior Medication: Required: * Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), or a combination thereof, for at least 2 months. Patients must have the following: * Diagnosis of AIDS. * Documented HIV seropositivity. * Ability to give informed consent and willingness to comply with visit schedule and all procedures.

Exclusion criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Lymphoma or visceral Kaposi's sarcoma. * Active peptic ulcer or bleeding disorder. * Hemophilia. Known intolerance to pentoxifylline, theophylline, or caffeine. Concurrent Medication: Excluded: * Warfarin and heparin. * Biological response modifiers (e.g., erythropoietin, interferon, G-CSF, GM-CSF). Cytotoxic chemotherapy. * Megestrol acetate. Corticosteroids. Concurrent Treatment: Excluded: * Radiation therapy. Blood products or transfusions. Patients with the following are excluded: * Presence of an active opportunistic infection. * Major surgery within 30 days of study treatment. Prior Medication: Excluded: * Biological response modifiers (including interferon, interleukin), corticosteroids, or megestrol acetate within 14 days of first (screening) TNF level. * Erythropoietin dependency or within 30 days of study treatment. Prior Treatment: Excluded: * Transfusion or blood product dependency or use within 30 days of study treatment.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026